Doximity Scribe

The artifact is wholly model generated, but the competitive asset is not the model. Doximity's moat is a professional network reaching more than 80 percent of United States physicians, built over fifteen years, and Scribe is given away free inside it. Nothing is being sold on model quality, which is the distinguishing feature of this entry: adoption will follow distribution and price rather than performance. Graded B on the same moat is not the model reasoning applied to Conveyor AI and Chartnote, and deliberately not the C given to EHR bundled products, because Scribe is a product a clinician actively chooses to open rather than a module inside a system they were already required to use.

Not assessed. No review gate, sign off step, confidence threshold, acceptance rate or edit burden figure is described in the located material. One structural observation stands in place of a grade: because no EHR write back is documented, the clinician necessarily handles the note before it reaches the chart, which functions as a default human gate in the same way it does for the transfer based products in this category. That is a consequence of the integration gap rather than a designed oversight mechanism.

The workflow is described in stages, live transcription then transcript processing then note generation, but nothing is measured. No accuracy figure, model card, named models or evaluation methodology was located, which is a notable omission for a product distributed at this scale. The beta produced millions of notes across more than 10,000 clinicians, so the data to publish an accuracy or edit burden figure plainly exists.

Adoption at scale is documented, with more than 10,000 clinicians generating millions of notes during a beta that ran over a year, but that measures usage rather than benefit. No study, controlled evaluation, accuracy benchmark, third party rating or published outcome data was located. Graded C on the standing precedent that scale of use does not substitute for evidence of benefit, the same call applied to Infervision, QuantHealth and Oracle Health.

One of the clearest data commitments in this category, stated plainly and without hedging: no audio is stored or retained, recordings are processed securely in real time and immediately discarded once the note is generated, and notes are private to the individual user rather than visible to an employer or organisation. Privacy to the clinician matters here in a way it does not for enterprise products, because a free tool adopted individually sits outside institutional oversight. One gap keeps the record honest rather than the grade: the commitment covers AUDIO, and no equivalent statement was located on whether generated notes or transcripts are used to train models.

The strongest position on this axis in the wave, and it is structural rather than promissory. Doximity states that ALL users are covered by a business associate agreement, which removes the question every other free or self serve product in this category leaves open. Elsewhere here a clinician can begin generating notes on a free tier before any agreement conversation happens; here coverage is automatic and universal. For a product that will be adopted by individual clinicians without procurement involvement, that is the single most important commercial safeguard.

Not assessed. No named or dated attestation was located for this product in this pass, though Doximity is a publicly listed company and a certification programme would be expected. Worth requesting rather than assuming.

Not a regulated medical device and none claimed or required for ambient documentation.

Nothing located. No fairness statement, subgroup analysis or accent and dialect performance disclosure. The absence carries more weight here than for a small vendor precisely because of reach: a documentation tool distributed free to a majority of United States physicians will encounter the full range of patient and clinician speech, and any performance variation across accent or dialect propagates at national scale rather than within one practice. Of every vendor in this index, this is among the best placed to publish subgroup performance and among the most consequential for not doing so.

The clearest limitation of the product. No integration with any electronic health record was located: the documented ecosystem connections are to Doximity's own products, Dialer for calls and telehealth and Ask for evidence queries, not to record systems. That means the note is generated outside the chart and the clinician moves it, so a free scribe still carries a manual transfer cost per encounter. For an individual clinician that may be an acceptable trade against a competitor charging hundreds a month; for a practice wanting structured data in the record it is disqualifying.

Not assessed. No hosting region, residency detail or sub processor information was located, though the no retention commitment on audio materially reduces what residency would protect.

There is nothing to disclose because there is nothing to pay, and the eligibility is stated precisely rather than buried: free to all verified United States physicians, nurse practitioners, physician assistants and medical students, with no tiers, no usage caps located, no upsell path and no procurement conversation. Against competitors in this category quoting hundreds of dollars per provider per month, that is a structural price position rather than a discount. Worth recording alongside it: Doximity provides Scribe, free onboarding assistance and Dialer Pro telemedicine at no cost to free and charitable clinics across the United States, which extends access to settings that generally cannot fund documentation technology at all.

Broad by eligibility rather than by tuning. Available to physicians, nurse practitioners, physician assistants and medical students across all specialties and practice areas, usable at in person visits and through Doximity Dialer for telehealth calls and video. Custom templates and freeform notes are supported. Held at B because no specialty specific models, specialty count or language coverage was located, and availability is United States only.